Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation.

Authors :: Maucherat B
Varmenot N
Fleury V
Senellart H
Rousseau C
Source :: Clinical nuclear medicine [Clin Nucl Med] 2021 Feb 01; Vol. 46 (2), pp. 144-145.
Publication Year :: 2021
Abstract: Abstract: Radiopharmaceutical extravasation is a known nuclear medicine adverse effect, mostly with no complication in case of diagnostic radiopharmaceutical. However, a therapeutic radiopharmaceutical extravasation may have clinical consequences and must be treated quickly and effectively. We report here a case of 177Lu-DOTA0-Tyr3-octreotate extravasation.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)